Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c539db959cc0106cab1662303f94fce |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
filingDate |
2008-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c1eff7ab437a2b8bdb6f367da918e99 |
publicationDate |
2009-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2009221186-A |
titleOfInvention |
Antiviral preparation |
abstract |
Disclosed is a topical formulation having significant efficacy in a topical antiviral composition comprising acyclovir, penciclovir and / or omaciclovir which are therapeutic agents for viral infections. A 15 to 25 wt% propylene glycol and 10 to 25 wt% isopropyl C 12 -C glucocorticoid containing 22 alkanoic acid esters - acyclovir in free pharmaceutical carrier, oil-in-water or oil containing penciclovir and / or omaciclovir A water-in-water topical antiviral composition. The composition is useful for the treatment or prevention of herpes virus infection. Clinical results have demonstrated that treatment starting in the progenitor phase can prevent the onset of typical cold sores in most patients. [Selection figure] None |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9339548-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014510756-A |
priorityDate |
2008-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |